Aurobindo Pharma's China Manufacturing Facility Expected to Reach Break-Even by Q3 FY26
核心洞察
Aurobindo Pharma's China facility, which began operations in November 2024, is expected to achieve break-even at the EBITDA level by Q3 FY26 after a USD 145 million investment.
The facility has an initial capacity of over 2 billion units and is currently ramping up production while beginning to contribute to revenue in the coming quarters.
The company has also invested USD 70 million in two US facilities and plans to file for more than 20 products in the US and Europe from its Visakhapatnam plant.
Aurobindo Pharma's newly operational China manufacturing facility is on track to achieve break-even at the EBITDA level by the third quarter of FY26, according to Chief Financial Officer Santhanam Subramanian (搜索). The Hyderabad-based pharmaceutical company commenced operations at the facility in the last week of November 2024 and is currently ramping up production.
Manufacturing Capacity and Investment
The China facility boasts an initial capacity of over 2 billion units and represents a significant USD 145 million investment by the company. "This facility with an initial capacity of 2 billion units plus is ramping up as expected and will begin contributing to revenue in the coming quarters and is expected to break even at the EBITDA (earnings before interest, taxes, depreciation, and amortisation) level by Q3 FY26," Subramanian stated during an analyst call.
The facility commenced production and invoicing in Q4 FY25 and Q1 FY26, respectively, marking a critical milestone in Aurobindo Pharma's international expansion strategy.
Broader Manufacturing Expansion
Beyond China, Aurobindo Pharma has invested approximately USD 70 million in two US facilities, with production expected to commence in the current fiscal year. The company's expansion strategy extends to its existing operations, with plans to file for more than 20 products in the US and Europe from its Eugia-V (搜索) plant in Visakhapatnam.
The pharmaceutical manufacturer has also committed USD 30 million to its Biologics CMO business, with an additional USD 100 million plus capital expected to be invested by March 2027.
Financial Performance and Outlook
Despite the significant investments in new facilities, Aurobindo Pharma reported a 10 percent year-on-year decline in consolidated net profit to Rs 824 crore for the June quarter, attributed to reduced sales in the US and API business vertical. However, revenue from operations increased to Rs 7,868 crore for the June quarter, compared to Rs 7,567 crore in the previous year.
"Looking ahead, we remain optimistic about sustaining our growth momentum. Our confidence is supported by expected volume expansion, continued product launches and a stable pricing environment, especially in the US and Europe," Subramanian noted.
Strategic Targets
The company maintains confidence in achieving its internal target margin of 20-21 percent in FY26. Subramanian emphasized that commercial operations ramping up at new manufacturing sites would further support topline growth and margin improvement in upcoming quarters.
The strategic investments across multiple geographies position Aurobindo Pharma to capitalize on global pharmaceutical market opportunities while diversifying its manufacturing footprint across key markets including China, the United States, and Europe.